Effect of tumor radiotherapy on the immune response

doi:10.3760/cma.j.issn.1673-422X.2015.06.013

Abstract

Abstract: Tumor radiation therapy (RT) can affect the immune system. Latest studies show that appropriate RT can activate the immune system through regulating tumor microenvironment, activating immune cells and releasing danger signals, and can produce bystander or abscopal effect. With the development of clinical biomarkers research and clinical trials about RT combined with immunotherapy, it is expected to change the traditional pattern of tumor treatment.

Key words: Radiotherapy, Neoplasms, Immunotherapy, Bystander effect

Kong Yuehong, Ding Jiping, Tu Wenyong. Effect of tumor radiotherapy on the immune response[J]. Journal of International Oncology, 2015, 42(6): 448-451.

References

［1］ Delaney G, Jacob S, Featherstone C, et al. The role of radiotherapy in cancer treatment:estimating optimal utilization from a review of evidencebased clinical guidelines［J］. Cancer, 2005, 104(6): 1129-1137. ［2］ Lavin MF. Ataxiatelangiectasia: from a rare disorder to a paradigm for cell signalling and cancer［J］. Nat Rev Mol Cell Biol, 2008, 9 (10): 759-769. ［3］ Shiao SL, Coussens LM. The tumorimmune microenvironment and response to radiation therapy［J］. J Mammary Gland Biol Neoplasia, 2010, 15(4): 411-421. ［4］ Germano G, Allavena P, Mantovani A. Cytokines as a key component of cancerrelated inflammation［J］. Cytokine, 2008, 43 (3): 374-379. ［5］ Gupta A, Probst HC, Vuong V, et al. Radiotherapy promotes tumorspecific effector CD8+ T cells via dendritic cell activation［J］. J Immunol, 2012, 189(2): 558-566. ［6］ Lee Y, Auh SL, Wang Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment［J］. Blood, 2009, 114 (3): 589-595. ［7］ Matsumura S, Wang B, Kawashima N, et al. Radiationinduced CXCL16 release by breast cancer cells attracts effector T cells［J］. J Immunol, 2008, 181(5): 3099-3107. ［8］ Burnette B, Weichselbaum RR. Radiation as an immune modulator［J］. Semin Radiat Oncol, 2013, 23 (4): 273-280. ［9］ Park B, Yee C, Lee K. The effect of radiation on the immune response to cancers［J］. Int J Mol Sci, 2014, 15(1): 927-943. ［10］ Lugade A, Sorensen E, Gerber S, et al. Radiationinduced IFNgamma production within the tumor microenvironment influences antitumor immunity［J］. J Immunol, 2008, 180 (5): 3132-3139. ［11］ Demaria S, Pilones KA, VanpouilleBox C, et al. The optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translation［J］. Radiat Res, 2014, 182(2): 170-181. ［12］ Yang KL, Wang YS, Chang CC, et al. Reciprocal complementation of the tumoricidal effects of radiation and natural killer cells［J］. PLoS One, 2013, 8(4): e61797. ［13］ Zitvogel L, Kepp O, Kroemer G. Decoding cell death signals in inflammation and immunity［J］. Cell, 2010, 140(6): 798-804. ［14］ Chaurio RA, Janko C, Munoz LE, et al. Phospholipids: key players in apoptosis and immune regulation［J］. Molecules, 2009, 14(12): 4892-4914. ［15］ Kolb R, Liu GH, Janowski AM, et al. Inflammasomes in cancer: a doubleedged sword［J］. Protein Cell, 2014, 5(1): 12-20. ［16］ Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death［J］. Nat Med, 2007, 13(1): 54-61. ［17］ Trabanelli S, Ocadlikova D, Gulinelli S, et al. Extracellular ATP exerts opposite effects on activated and regulatory CD4+ T cells via purinergic P2 receptor activation［J］. J Immunol, 2012, 189(3): 1303-1310. ［18］ Gaipl US, Multhoff G, Scheithauer H, et al. Kill and spread the word: stimulation of antitumor immune responses in the context of radiotherapy［J］. Immunotherapy, 2014, 6 (5): 597-610. ［19］ Bianchi ME. DAMPs, PAMPs and alarmins:all we need to know about danger［J］. J Leukoc Biol, 2007, 81(1): 1-5. ［20］ Turk MJ, GuevaraPatio JA, Rizzuto GA, et al. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells［J］. J Exp Med, 2004, 200(6): 771-782. ［21］ Qu Y, Jin S, Zhang A, et al. Gammaray resistance of regulatory CD4+CD25+Foxp3+ T cells in mice［J］. Radiat Res, 2010, 173(2): 148-157. ［22］ Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma［J］. N Engl J Med, 2012, 366(10): 925-931. ［23］ Schaue D, CominAnduix B, Ribas A, et al. Tcell responses to survivin in cancer patients undergoing radiation therapy［J］. Clin Cancer Res, 2008, 14(15): 4883-4890. ［24］ Chen W, Jin W, Hardegen N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGFbeta induction of transcription factor Foxp3［J］. J Exp Med, 2003, 198(12): 1875-1886. ［25］ Suzuki Y, Mimura K, Yoshimoto Y, et al. Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma［J］. Cancer Res, 2012, 72(16): 3967-3976. ［26］ Paul S, Smilenov LB, Amundson SA. Widespread decreased expression of immune function genes in human peripheral blood following radiation exposure［J］. Radiat Res, 2013, 180(6): 575-583. ［27］ ElSaghire H, Thierens H, Monsieurs P, et al. Gene set enrichment analysis highlights different gene expression profiles in whole blood samples Xirradiated with low and high doses［J］. Int J Radiat Biol, 2013, 89(8): 628-638. ［28］ Palma P, Cuadros M, CondeMuino R, et al. Microarray profiling of mononuclear peripheral blood cells identifies novel candidate genes related to chemoradiation response in rectal cancer［J］. PLoS One, 2013, 8(9): e74034. ［29］ Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of antiPDL1 antibody in patients with advanced cancer［J］. N Engl J Med, 2012, 366(26): 2455-2465. ［30］ Lipson EJ, Sharfman WH, Drake CG, et al. Durable cancer regression offtreatment and effective reinduction therapy with an antiPD1 antibody［J］. Clin Cancer Res, 2013, 19 (2): 462-468.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[3]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[4]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[5]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[6]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[7]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[8]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[9]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[10]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[11]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[12]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[13]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[14]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[15]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.